A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer

Chih Ming Su, Ting Yu Chang, Hui Ping Hsu, Hui Huang Lai, Jie Ning Li, Yu Jhen Lyu, Kuang Tai Kuo, Ming Te Huang, Jen Liang Su, Pai Sheng Chen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) is commonly overexpressed in breast cancer and is associated with poor clinical outcomes; however, an increasing number of patients have shown a poor effective response to EGFR tyrosine kinase inhibitors (EGFR-TKI). Here, we found that AXL expression was positively correlated with poor progression in breast cancer patients. Suppression of AXL by an anti-tumor protein, E1A, enhanced EGFR-TKI (gefitinib, erlotinib and lapatinib) sensitization, resulting in significant inhibition of tumor growth in breast cancer cells. Additionally, AXL overexpression dramatically impaired E1A-mediated EGFR-TKI sensitization. These findings show that downregulation of AXL expression by E1A contributes to sensitization to EGFE-TKI in breast cancer, suggesting that combinatorial therapy of AXL inhibitors or E1A gene therapy with EGFR-TKI may be a potential therapeutic strategy for treatment of breast cancer patients.

Original languageEnglish
Pages (from-to)63924-63936
Number of pages13
JournalOncotarget
Volume7
Issue number39
DOIs
Publication statusPublished - 2016

Fingerprint

Epidermal Growth Factor Receptor
Breast Neoplasms
Therapeutics
Genetic Therapy
Protein-Tyrosine Kinases
Neoplasms
Down-Regulation
Growth
Proteins

Keywords

  • Combination therapy
  • E1A

ASJC Scopus subject areas

  • Oncology

Cite this

Su, C. M., Chang, T. Y., Hsu, H. P., Lai, H. H., Li, J. N., Lyu, Y. J., ... Chen, P. S. (2016). A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer. Oncotarget, 7(39), 63924-63936. https://doi.org/10.18632/oncotarget.11737

A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer. / Su, Chih Ming; Chang, Ting Yu; Hsu, Hui Ping; Lai, Hui Huang; Li, Jie Ning; Lyu, Yu Jhen; Kuo, Kuang Tai; Huang, Ming Te; Su, Jen Liang; Chen, Pai Sheng.

In: Oncotarget, Vol. 7, No. 39, 2016, p. 63924-63936.

Research output: Contribution to journalArticle

Su, Chih Ming ; Chang, Ting Yu ; Hsu, Hui Ping ; Lai, Hui Huang ; Li, Jie Ning ; Lyu, Yu Jhen ; Kuo, Kuang Tai ; Huang, Ming Te ; Su, Jen Liang ; Chen, Pai Sheng. / A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer. In: Oncotarget. 2016 ; Vol. 7, No. 39. pp. 63924-63936.
@article{e44195a31cb049d3baaeb7de4dec6400,
title = "A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer",
abstract = "Epidermal growth factor receptor (EGFR) is commonly overexpressed in breast cancer and is associated with poor clinical outcomes; however, an increasing number of patients have shown a poor effective response to EGFR tyrosine kinase inhibitors (EGFR-TKI). Here, we found that AXL expression was positively correlated with poor progression in breast cancer patients. Suppression of AXL by an anti-tumor protein, E1A, enhanced EGFR-TKI (gefitinib, erlotinib and lapatinib) sensitization, resulting in significant inhibition of tumor growth in breast cancer cells. Additionally, AXL overexpression dramatically impaired E1A-mediated EGFR-TKI sensitization. These findings show that downregulation of AXL expression by E1A contributes to sensitization to EGFE-TKI in breast cancer, suggesting that combinatorial therapy of AXL inhibitors or E1A gene therapy with EGFR-TKI may be a potential therapeutic strategy for treatment of breast cancer patients.",
keywords = "Combination therapy, E1A",
author = "Su, {Chih Ming} and Chang, {Ting Yu} and Hsu, {Hui Ping} and Lai, {Hui Huang} and Li, {Jie Ning} and Lyu, {Yu Jhen} and Kuo, {Kuang Tai} and Huang, {Ming Te} and Su, {Jen Liang} and Chen, {Pai Sheng}",
year = "2016",
doi = "10.18632/oncotarget.11737",
language = "English",
volume = "7",
pages = "63924--63936",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "39",

}

TY - JOUR

T1 - A novel application of E1A in combination therapy with EGFR- TKI treatment in breast cancer

AU - Su, Chih Ming

AU - Chang, Ting Yu

AU - Hsu, Hui Ping

AU - Lai, Hui Huang

AU - Li, Jie Ning

AU - Lyu, Yu Jhen

AU - Kuo, Kuang Tai

AU - Huang, Ming Te

AU - Su, Jen Liang

AU - Chen, Pai Sheng

PY - 2016

Y1 - 2016

N2 - Epidermal growth factor receptor (EGFR) is commonly overexpressed in breast cancer and is associated with poor clinical outcomes; however, an increasing number of patients have shown a poor effective response to EGFR tyrosine kinase inhibitors (EGFR-TKI). Here, we found that AXL expression was positively correlated with poor progression in breast cancer patients. Suppression of AXL by an anti-tumor protein, E1A, enhanced EGFR-TKI (gefitinib, erlotinib and lapatinib) sensitization, resulting in significant inhibition of tumor growth in breast cancer cells. Additionally, AXL overexpression dramatically impaired E1A-mediated EGFR-TKI sensitization. These findings show that downregulation of AXL expression by E1A contributes to sensitization to EGFE-TKI in breast cancer, suggesting that combinatorial therapy of AXL inhibitors or E1A gene therapy with EGFR-TKI may be a potential therapeutic strategy for treatment of breast cancer patients.

AB - Epidermal growth factor receptor (EGFR) is commonly overexpressed in breast cancer and is associated with poor clinical outcomes; however, an increasing number of patients have shown a poor effective response to EGFR tyrosine kinase inhibitors (EGFR-TKI). Here, we found that AXL expression was positively correlated with poor progression in breast cancer patients. Suppression of AXL by an anti-tumor protein, E1A, enhanced EGFR-TKI (gefitinib, erlotinib and lapatinib) sensitization, resulting in significant inhibition of tumor growth in breast cancer cells. Additionally, AXL overexpression dramatically impaired E1A-mediated EGFR-TKI sensitization. These findings show that downregulation of AXL expression by E1A contributes to sensitization to EGFE-TKI in breast cancer, suggesting that combinatorial therapy of AXL inhibitors or E1A gene therapy with EGFR-TKI may be a potential therapeutic strategy for treatment of breast cancer patients.

KW - Combination therapy

KW - E1A

UR - http://www.scopus.com/inward/record.url?scp=84993982792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993982792&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11737

DO - 10.18632/oncotarget.11737

M3 - Article

AN - SCOPUS:84993982792

VL - 7

SP - 63924

EP - 63936

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 39

ER -